🔎 Trials Near Me

Home › NCT07820891

A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395

RecruitingPhase 1Healthy volunteers welcome

A Phase 1, Open-label, Fixed-sequence Trial in Healthy Participants to Assess the Drug Interaction Potential of BGB-43395 With A Drug Cocktail Representative for CYP3A4, CYP2C9, P-gp, and BCRP Substrates

Who can join

Ages 18 to 65 · All sexes · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria:

* Body mass index between 18.0 and 32.0 kg/m\^2, inclusive.
* In good health, as determined by no clinically significant findings from medical history, 12-lead electrocardiogram and vital signs measurements, and clinical laboratory assessments.
* Participants must not be pregnant or lactating and must agree to use contraception.

Exclusion Criteria:

* Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator
* History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs
* Confirmed systolic blood pressure \>140 or \<90 mmHg, diastolic blood pressure \>90 or \<50 mmHg, or pulse rate \>100 or \<40 beats per minute.

Note: Other protocol-defined inclusion and exclusion criteria may apply.

About the study

This study will enroll healthy participants to evaluate whether BGB-43395 interacts with other drugs, including midazolam, celecoxib, dabigatran, and rosuvastatin.

What is being tested

Sponsor: BeOne Medicines · Participants: 24 · Started: Sep 25, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07820891

Locations in the U.S.

TexasFortrea Clinical Research Unit, Dallas

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.